Completed Projects

HOME > R&D Pipeline > Current status > Completed Projects

KDDF-201404-04 Development of lead componds for rheumatoid arthritis therapy by using cytokine-derived peptide SIS-1(Immunology, Protein) [08.05.2014]

PRINT

Development and Market Objectives

The development objective is to generate lead compounds as a novel therapy to treat rheumatoid arthritis based on a Erdr1-derived peptide SIS-1 that has been observed to exhibit anti-inflammatory effects and improvement of rheumatoid arthritis in CIA mouse model.

Unmet Medical Need & Target Patients

Currently prescribed drugs to treat rheumatoid arthritis include TNF inhibitors, which are primarily focused on easing of symptoms rather than a cure of the disease. The percentage of patients reporting a 70% improvement in terms of symptoms is only around 15%, while that of the patient group with very low reactivity (patients who do not reach ACR20) is approximately 30%. In addition, considering drug resistance issues and severe side effects, the developments of new medicines that address these problems are critically needed.
 
Recently, interest in the use of biologicals with a different mechanism-of-action to TNF inhibitors has been increasing. Therefore, needs of new developmental therapeutics with novel mechanisms has been recognized by the medical community.
 
Our research team attempts to develop therapeutic lead compounds for rheumatoid arthritis therapy by using Erdr1-derived peptide SIS-1 with novel mechanism-of-action. It targets a novel inflammatory cytokine control mechanism by focusing on the fact that the amount of inflammatory cytokines such as IL-17 remains high after treatment in TNF-refractory patient groups. Evidence suggests that the amount of inflammatory cytokines such as IL-18/IL-32 increases in rheumatoid arthritis patients.

Status

- Establishment of the optimal efficacy of SIS-1 for RA therapy in CIA mouse model
- Generation of three lead compounds for RA therapy in CIA mouse model 
- Verifying the inhibitory function of Erdr1/SIS-1/three lead compounds toward inflammatory cytokines
- Verifying the inhibitory function of Erdr1/SIS-1/ three lead compounds toward polarized Th17 cells
- Verifying the inhibitory function of Erdr1/SIS-1/ three lead compounds toward osteoclast differentiation
- Identification of two targets for Erdr1/SIS-1 binding

Intellectual Property

- PCT application PCTKR20131005912
- Domestic registration 10-1510941
- Domestic application 10-2012-0072513
- Domestic application 10-2016-0028227
- Domestic application 10-2016-0028229
- Securing of substance patent
- Progressing with patent protection in 10 major countries


 

Competitive Advantages

Development of a novel therapeutic target that is highly effective on TNF inhibitor refractory patients by targeting a different mechanism to that of TNF inhibition.
‘First-in-class’ investigation of the therapeutic potential of Erdr1 which has been implicated with anti-cancer and anti-inflammatory effects
Domestic licensing-out is in progress via joint research with domestic and overseas pharmaceutical companies through continuous contact. The possibility of a successful international licensing deal is high.
 

Indication

Rheumaoid Arthitis    

Research Period

July, 2014 ~ June, 2016

Company

Sookmyung university

Developmental Stage

Lead
    

Additional Information

Contact Information

Contact
Address Company Name: Sookmyung University
WebSite Homepage: http://sookmyung.ac.kr/~cdhkor Contact Person: Prof. Daeho Cho
E-mail: cdhkor@sookmyung.ac.kr/kyungeun@sookmyung.ac.kr Contact: +82-2-710-9416

Related Projects

Related Project
list
Update to 2013 © KOREA DRUG DEVELOPMENT FUND. ALL RIGHTS RESERVED. QR Code